$0.60
6.29% today
NYSE, Feb 28, 05:24 pm CET
ISIN
US9286611077
Symbol
VNRX
Sector

VolitionRX Stock price

$0.64
+0.06 10.65% 1M
-0.06 8.61% 6M
+0.04 6.53% YTD
-0.35 35.45% 1Y
-2.28 78.11% 3Y
-2.69 80.80% 5Y
-3.47 84.46% 10Y
NYSE, Closing price Thu, Feb 27 2025
+0.06 9.45%
ISIN
US9286611077
Symbol
VNRX
Sector

Key metrics

Market capitalization $61.34m
Enterprise Value $60.68m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 47.04
P/S ratio (TTM) P/S ratio 47.55
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 97.50%
Revenue (TTM) Revenue $1.29m
EBIT (operating result TTM) EBIT $-29.98m
Free Cash Flow (TTM) Free Cash Flow $-14.48m
Cash position $5.41m
EPS (TTM) EPS $-0.36
P/E forward negative
P/S forward 42.10
EV/Sales forward 41.65
Short interest 0.67%
Show more

Is VolitionRX a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

VolitionRX Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a VolitionRX forecast:

2x Buy
67%
1x Hold
33%

Analyst Opinions

3 Analysts have issued a VolitionRX forecast:

Buy
67%
Hold
33%

Financial data from VolitionRX

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
1.29 1.29
98% 98%
100%
- Direct Costs 1.34 1.34
1% 1%
104%
-0.06 -0.06
92% 92%
-5%
- Selling and Administrative Expenses 13 13
13% 13%
1,039%
- Research and Development Expense 15 15
15% 15%
1,177%
-29 -29
16% 16%
-2,220%
- Depreciation and Amortization 1.34 1.34
1% 1%
104%
EBIT (Operating Income) EBIT -30 -30
15% 15%
-2,324%
Net Profit -30 -30
12% 12%
-2,316%

In millions USD.

Don't miss a Thing! We will send you all news about VolitionRX directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

VolitionRX Stock News

Neutral
PRNewsWire
about 3 hours ago
Volition will showcase presentations from Dr. Sue Ettinger, aka Dr. Sue Cancer Vet, Dr. Brett Cordes, DVM, and Dr. Tom Butera, DVM Representatives will also be available at exhibition booth #2943 HENDERSON, Nev. , Feb. 28, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, Volition is pleased to announce our participation in the 97t...
Neutral
PRNewsWire
22 days ago
Expanding commercial offering as a bio-partnering model, currently in active discussions with pharmaceutical companies  HENDERSON, Nev. , Feb. 6, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) Volition a multi-national epigenetics company, announces its first commercial sale of Volition's High Throughput Synthetic Sepsis method that measures Neutrophil Extracellular Traps "NETs" ...
Neutral
PRNewsWire
23 days ago
HENDERSON, Nev. , Feb. 5, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced it will host a virtual investor event on Friday, February 14, 2025 at 8:00 AM ET, featuring Volition company management Dr. Andrew Retter, Chief Medical Officer and Gael Forterre, Chief Commercial Officer.
More VolitionRX News

Company Profile

VolitionRX Ltd. engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluids. The company was founded on September 24, 1998 and is headquartered in Henderson, NV.

Head office United States
CEO Cameron Reynolds
Employees 110
Founded 1998
Website www.volition.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today